WallStreetZenWallStreetZen

NYSE: PFE
Pfizer Inc Earnings & Revenue

Open Broker Account
OverviewForecastEarnings
DividendOwnershipStatistics

PFE past earnings growth

How has PFE's earnings growth performed historically?
Company
53.47%
Industry
39.22%
Market
41.86%
PFE's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
PFE's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
PFE's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

PFE past revenue growth

How has PFE's revenue growth performed historically?
Company
44.72%
Industry
12.59%
Market
195.06%
PFE's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
PFE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
PFE's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

PFE earnings and revenue history

Current Revenue
$99.7B
Current Earnings
$29.8B
Current Profit Margin
29.9%
PFE's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

PFE Return on Equity

Current Company
35.1%
Current Industry
48.8%
Current Market
-8.3%
PFE's Return on Equity (35.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when PFE announces earnings.

PFE Return on Assets

Current Company
15.8%
Current Industry
11.3%
PFE is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

PFE Return on Capital Employed

Current Company
21.98%
Current Industry
17.8%
PFE has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PFE vs General Drug Manufacturer Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
PFE$99.68B$38.03B$29.77B+13.69%+26.49%
ABBV$57.82B$25.20B$13.41B+16.22%+12.65%
MRK$58.97B$20.62B$15.26B+8.18%+42.12%
LLY$29.24B$8.14B$6.03B+5.41%+25.80%
AZN$45.15B$8.60B$2.04B+15.18%-16.89%
View Top General Drug Manufacturer Stocks

Pfizer Earnings & Revenue FAQ

What were PFE's earnings last quarter?

On Invalid Date, Pfizer (NYSE: PFE) reported Q3 2022 earnings per share (EPS) of $1.54, up 6.21% year over year. Total Pfizer earnings for the quarter were $8.61 billion. In the same quarter last year, Pfizer's earnings per share (EPS) was $1.45.

If you're new to stock investing, here's how to buy Pfizer stock.

What was PFE's earnings growth in the past year?

As of Q4 2022, Pfizer's earnings has grown 53.47% year over year. This is 14.25 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 39.22%. Pfizer's earnings in the past year totalled $29.77 billion.

What was PFE's revenue last quarter?

On Invalid Date, Pfizer (NYSE: PFE) reported Q3 2022 revenue of $22.64 billion up 5.81% year over year. In the same quarter last year, Pfizer's revenue was $24.04 billion.

What was PFE's revenue growth in the past year?

As of Q4 2022, Pfizer's revenue has grown 44.72% year over year. This is 32.13 percentage points higher than the US Drug Manufacturers - General industry revenue growth rate of 12.59%. Pfizer's revenue in the past year totalled $99.68 billion.
©2022 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.